Peptide research profile
Liraglutide
Also known as Saxenda · Victoza
The SCALE randomized trial found greater weight reduction with liraglutide plus lifestyle intervention than with placebo plus lifestyle intervention. Product labels differ by indication and eligible population.
High evidenceFDA approved
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 2
- Side-effect records
- 146Named most often: Nausea · Dizziness · Vomiting
Educational. Not medical advice.
Summary
A daily GLP-1 receptor agonist with FDA-approved products for weight management and diabetes-related indications.
What is Liraglutide being studied for?
Weight management and type 2 diabetes
How is it thought to work?
Activates the GLP-1 receptor to affect glucose-dependent insulin secretion, glucagon, appetite, and gastric emptying.
Recorded outcomes
146 side-effect records on Liraglutide
Free account3 graded outcomes and 2 sources for Liraglutide.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.